Global Moot Corp, tonight announced the Global Champion of its competition is BiologicsMD, a team from the University of Arkansas, developing a new prescription medicine for the treatment of osteoporosis. Biologics MD is developing OsteoFlorTM, a new prescription medicine for the treatment of osteoporosis, based on research developed at the University of Arkansas. OsteoFlorTM binds directly to the bone, nearly tripling new bone growth. Paul Mlakar, President of BiologicsMD said “It’s a great honor to have won this prestigious competition, and we look forward to following the path of other winners in launching our company.” In addition to announcing its Global Champion, the competition also announced it is changing its name to the “Venture Labs Investment Competition” and repositioning itself as “The Super Bowl of Investment Competition.” It will continue to use its former name, “Moot Corp,” as part of its tagline for the foreseeable future. Rob Adams, director of the Venture Labs Investment Competition, explained the renaming as “reflective of the true nature of what Moot Corp had turned into, a forum where MBAs from around the world launch their ventures by raising capital. This competition is far from Moot, and parallels the real-world process and realities of developing and launching a venture backed company. This renaming and repositioning aligns the competition with that mission.” This year’s competition involved 40 teams from 12 countries and included categories from clean energy to biotechnology to information technology to consumer products. As always, teams must have won a Global Moot Corp regional feeder competition to make it to the Global Competition. These teams presented a minimum of three times throughout the competition, always to a new set of judges, as the teams were whittled down to the final four. In addition to its prize money, BiologicsMD will be present with the Global Moot Corp team to close the NASDAQ market on Friday, June 11 in Times Square, New York City.
Footer
